By Joe Cintavey, Product Manager, GORE PharmBIO
Due to the worldwide response to COVID-19-related R&D; increased development of novel therapeutics; and the expansion of cell and gene therapy innovations, biopharma manufacturers are seeing significant manufacturing momentum. Biopharmaceuticals are a large market that's growing at a steady rate, and gene and cell therapies are showing tremendous promise with more than 1000 cell and gene therapy clinical trials currently in progress worldwide.
Emerging cell and gene therapies and other more established therapeutics have immense potential for patients in need of life-saving treatments, and as solutions are developed and manufactured, a reliable supply chain is critical for both drug substance and drug product transport. Specifically, storing and safely distributing these materials to ensure quality is essential for ultimately improving patient outcomes. Drug substance transportation, as part of the complete journey to the manufacture of final products, can be compromised without reliable cold storage strategies but managing and maintaining a proper cold chain in pharmaceutical manufacturing is often complicated. There are many factors that manufacturers must consider when transporting substances, including packaging durability, ensuring that products are not damaged during transportation, and maintaining optimal temperature to make sure they don’t degrade.
Learn why it's important for manufacturers to choose the most durable and innovative primary packaging, and how to eliminate potential issues during supply chain transportation phases.